Supplements

Dupilumab improves patient-reported sleep quality in patients with severe, uncontrolled CRSwNP

A systematic review of 7 studies (n=2164) found that dupilumab consistently improved sleep quality outcomes in CRSwNP patients, including SNOT-22 sleep domain (mean reduction up to -7.02 points at 24 weeks, p<0.001), PSQI, ESS, and ISI scores. One study reported a decrease in poor global sleep quality from 88.9% at baseline to 5.7% at 12 months. However, evidence is limited by lack of objective sleep measures and high risk of bias in observational studies.

Last updated: Aug 16, 2026•0 RCTs•1 Meta-analyses•📖 Read as article →

Evidence Score

Evidence Score49/100
Human RCT☆☆☆☆☆
Meta-analysis★★★☆☆
Mechanism★★★★★
Safety★★★★☆
Confidencelow

Study Evidence

Study 1. Could Dupilumab Improve Sleep Quality in CRSwNP Patients: Myth or Reality? A Systematic Review.

observational

Moffa A, De Corso E, Nardelli D, Bahgat AY, Loperfido A, Afifi IA, Olszewska E, Baptista PM, Galli J, Casale M · Journal of clinical medicine (2026)

Participants: N/A
Duration: Up to 12 months (studies varied; SNOT-22 improvement at 24 weeks)
Intervention: Dupilumab 300 mg every 15 days for at least 1 month
Outcome: Sleep quality measured by SNOT-22 sleep domain, PSQI, ESS, ISI
Effect Size: SNOT-22 sleep domain mean reduction up to -7.02 points at 24 weeks
Population: Adults with severe, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP)

Result:

PubMed: 42590112DOI: 10.3390/jcm15156010

Mechanism Graph

Dupilumab blocks IL-4 receptor alpha, inhibiting IL-4 and IL-13 signaling
↓
Reduces type 2 inflammation in nasal polyps and sinonasal mucosa
↓
Decreases nasal obstruction and other sinonasal symptoms
↓
May directly improve sleep architecture by reducing cytokine-mediated disruption
↓
Result: Improved patient-reported sleep quality

Limitations

  • ⚠No polysomnographic data reported; only patient-reported outcomes
  • ⚠Most observational studies had serious risk of bias due to unaddressed confounding and lack of blinding
  • ⚠Lack of comparative head-to-head data with other treatments

Frequently Asked Questions

How does dupilumab improve sleep quality in CRSwNP patients?▼

Dupilumab blocks IL-4/IL-13 signaling, reducing type 2 inflammation and nasal obstruction, which may also directly improve sleep architecture. The review found significant improvements in patient-reported sleep measures.

What sleep outcomes were measured in the studies?▼

The studies used validated tools including the SNOT-22 sleep domain, Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), and Insomnia Severity Index (ISI).

What is the recommended dose of dupilumab for CRSwNP?▼

The studies included patients receiving dupilumab 300 mg every 15 days for at least one month, which is the approved dose for severe CRSwNP.

Are there any objective sleep measurements in this review?▼

No, the review found no polysomnographic data. All sleep outcomes were patient-reported, which is a limitation of the evidence.

Products

Affiliate links coming soon. We only recommend products that match the doses and forms used in the cited research.

References

  1. 1.Moffa A, De Corso E, Nardelli D, Bahgat AY, Loperfido A, Afifi IA, Olszewska E, Baptista PM, Galli J, Casale M. "Could Dupilumab Improve Sleep Quality in CRSwNP Patients: Myth or Reality? A Systematic Review.." Journal of clinical medicine, 2026. PMID: 42590112 DOI: 10.3390/jcm15156010
Disclaimer: This content is for educational purposes only and is not medical advice. Evidence scores reflect the quality and quantity of available research, not clinical recommendations. Always consult a healthcare professional before starting any supplement or intervention.